THMO ThermoGenesis Holdings, Inc.

Cesca Therapeutics, Inc. engages in the research, development, commercialization and marketing of automated technologies for cell-based therapies for use in regenerative medicine. It operates through the following segments: Device and Clinical Development. The Device segment includes development and commercialization of automated systems that provide good manufacturing practice, clinical grade cell-banking, cell-processing and cell-based therapeutics. The Clinical Development segment develops autologous stem cell-based therapeutics that address significant unmet medical needs for the vascular, cardiology, and orthopedic markets. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

$2.94
As of 06/11/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  10/28/2019
Outstanding shares:  11,911,784
Average volume:  289,164
Market cap:   $34,186,820
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    88362L100
ISIN:        US88362L1008
Sedol:      BK4KSP6
Valuation   (See tab for details)
PE ratio:   -2.47
PB ratio:   3.34
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy